Company Profile
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company provides the research and development, manufacture, and marketing of cellular immunotherapy products in the People's Republic of China. The company offers cell-based immunotherapies, including CAR-T treatment, a treatment method that uses human immune cells to fight cancer.
It offers Carteyva, JWCAR201, and JWCAR239 for the treatment of hematological malignancies, advanced relmacabtagene autoleucel injection (ยrelma-celย) as a potential treatment for systemic lupus erythematosus (ยSLEย), and progressed development of products for the treatment of solid tumors systemic lupus erythematosus (SLE), a chronic autoimmune disease.
The company's products pipeline includes JWCAR129, a chimeric antigen receptor (CAR) construct therapy for use in the treatment of multiple myeloma JWCAR201, a dual targeting autologous CAR T-cell therapy for use in the treatment of B-cell malignancies and autoimmune diseases.
It is also developing JWATM204 and JWATM214 for treating hepatocellular carcinoma (HCC). Its portfolio also includes JWATM203 for the treatment of hepatoblastoma (HB) and hepatocellular carcinoma (HCC) in pediatric patients, JWATM213 for treating HCC, JWTCR001 for the treatment of various solid tumors, and JWCAR031 for the treatment of small cell lung cancer.
Additionally, it engages in drug R&D. Its portfolio also includes medical research and experimental development, import and export handling, and clinical trial and CRO investment holding activities. Founded in 2016, JW (Cayman) Therapeutics is headquartered in Shanghai, China.